United States· US:59572-515_4adbd9af-42bb-4e51-86fc-b06ccd213b43
Abecma
A idecabtagene vicleucel product containing idecabtagene vicleucel, registered in United States by Celgene Corporation. The same ATC class is registered in 10 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Idecabtagene vicleucel is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XL07 (idecabtagene vicleucel), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Idecabtagene vicleucel · ATC L01XL07
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- IDECABTAGENE VICLEUCEL
- Manufacturer
- Celgene Corporation
- Country
- United States (US)
- ATC code
- L01XL07
- ATC class
- Idecabtagene vicleucel
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 3
- ndc1159572-515-02
- ndc1159572-515-03
- ndc1159572-515-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idecabtagene vicleucel in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAbecma 260-500 x 10*6 cellsBristol-Myers Squibb Pharma
- SwitzerlandAbecma Infusionsdispersion, von 260 bis 500 × 10e6 CAR-positiven lebensfähigen T-ZellenBristol-Myers Squibb SA
- CzechiaABECMABristol-Myers Squibb Pharma EEIG, Dublin
- SpainABECMA 260-500 x 10e6 CELULAS DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandAbecmaBristol-Myers Squibb Pharma EEIG
- FranceABECMA 260 - 500 x 1 000 000 cellules, dispersion pour perfusionBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- IrelandAbecma 260 - 500 x 106 cells dispersion for infusionBristol-Myers Squibb Pharmaceuticals uc
- IcelandAbecmaBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Abecma
- Liechtenstein · Abecma
- Norway · Abecma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/52bf33aa-66c6-45e5-9b38-adb6b83f2efe GET /v1/drugs/52bf33aa-66c6-45e5-9b38-adb6b83f2efe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "300000000",
"substance": "IDECABTAGENE VICLEUCEL",
"productndc": "59572-515",
"dosage_form": "SUSPENSION",
"dea_schedule": null,
"strength_unit": "1/1",
"application_number": "BLA125736",
"marketing_category": "BLA"
}See everything about idecabtagene vicleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.